Format

Send to

Choose Destination
Clin Pharmacol Ther. 2017 Sep;102(3):502-510. doi: 10.1002/cpt.630. Epub 2017 Jun 9.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Author information

1
Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
2
Center for Pharmacogenomics, College of Medicine, Ohio State University, Columbus, Ohio, USA.
3
Program for Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
4
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
5
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
6
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
7
Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
8
Stanford University School of Medicine, Palo Alto, California, USA.
9
Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
10
Office of Research Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
11
Department of Statistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
12
Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA.
13
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
14
Department of Biomedical Informatics, Ohio State University, Columbus, Ohio, USA.
15
Department of Cancer Biology and Genetics, College of Medicine, Ohio State University, Columbus, Ohio, USA.
16
Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
17
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.

Abstract

Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the National Institutes of Health (NIH) Pharmacogenomics Research Network was established in 2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US healthcare systems, with the goal to disseminate real-world solutions for the barriers to clinical pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementation metrics through June 2015, including gene-drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, educational, financial, and informatics), which may inform healthcare systems seeking to implement their own pharmacogenetic testing programs.

PMID:
28090649
PMCID:
PMC5511786
DOI:
10.1002/cpt.630
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center